Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma
Objective: First-line chemotherapy in metastatic neuroendocrine carcinomas (NECs) is based on etoposide and platinum. However, there is no standard concerning second-line treatment. The objective of this study was to evaluate effic acy and tolerance of dacarbazine or temozolomide in metastatic diges...
Main Authors: | Thomas Couronne, Paul Girot, Julien Hadoux, Thierry Lecomte, Alice Durand, Caroline Fine, Katia Vandevoorde, Catherine Lombard-Bohas, Thomas Walter |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2020-06-01
|
Series: | Endocrine Connections |
Subjects: | |
Online Access: | https://ec.bioscientifica.com/view/journals/ec/aop/ec-20-0192/ec-20-0192.xml |
Similar Items
-
Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
by: Kotteas EA, et al.
Published: (2016-02-01) -
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
by: Katharine Thomas, et al.
Published: (2020-01-01) -
Neoadjuvant Chemotherapy with Capecitabine and Temozolomide for Unresectable Pancreatic Neuroendocrine Tumor
by: Sumana Devata, et al.
Published: (2012-11-01) -
Exceptional response to neoadjuvant capecitabine and temozolomide in TSC2-mutant pancreatic neuroendocrine tumor
by: Robin Park, et al.
Published: (2020-12-01) -
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
by: Salvatore Tafuto, et al.
Published: (2019-08-01)